About Vanda Pharmaceuticals Inc. - Common Stock (VNDA)
Vanda Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies to address unmet medical needs in the fields of central nervous system disorders and sleep disorders. The company is dedicated to improving the lives of patients through its specialized drug products, which aim to treat conditions such as schizophrenia and insomnia. Vanda's research and development efforts are primarily geared towards advancing its pipeline of proprietary medicine, leveraging scientific expertise and clinical insight to enhance treatment options for patients around the world. Read More
WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP).
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors’ and officers’ possible violations of state laws.
HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product portfolio, and growth in neurology.
The FDA rejected Vanda Pharmaceuticals' new drug application for tradipitant to treat gastroparesis, citing the need for more studies despite delays in its review process. Vanda argues the drug meets efficacy standards and plans to continue pursuing approval.
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves targeted at specific brain regions and has shown promise in easing symptoms for patients with treatment-resistant bipolar disorder.1 Initially approved for major depressive disorder by the FDA, iTBS offers … Continue reading "Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment"
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors’ and officers’ possible violations of state laws.
